Gastric cancer (GC) is currently the fourth most common malignancy and the second leading cause of cancer death in the world, with an estimate of 989 000 new cases and 738 000 deaths in 2008 ([@bib5]). However, nearly half of global GC cases (464 000) and deaths (352 000) occur in China ([@bib5]). Early GC is typically small and asymptomatic, and the high mortality from GC is mainly due to late presentation ([@bib6]). Therefore, early detection and treatment is an important way to reduce death from GC. Several tests have been applied in population screening, such as barium meal and endoscopy, especially in Japan, with an ultimate goal of reducing mortality associated with GC ([@bib14]). However, these approaches may be not eligible for mass screening and early detection of GC in most countries including China for the reasons such as acceptance, availability and cost. In addition, non-invasive serological tests, such as serum pepsinogen and gastrin-17, however, have no sufficient sensitivity and specificity to facilitate the early detection ([@bib14]). Therefore, efforts should be invested in the discovery of novel, reliable and non-invasive biomarkers for mass screening and early detection of GC.

MicroRNAs (miRNAs) are a class of small non-coding RNAs that can repress translation or promote degradation of target mRNAs of complementary sequences. A single miRNA can influence the expression of hundreds of target genes, and miRNAs have been implicated as key molecules in various diseases, including cancer ([@bib29]). Although the molecular mechanisms of miRNAs are incompletely understood in the process of carcinogenesis, specific patterns of miRNA expression have been associated with almost every type of tumour ([@bib23]), suggesting diagnostic and prognostic potentials for miRNAs. More importantly, circulating miRNAs can be stably detected in the peripheral blood ([@bib3]; [@bib18]), though the exact source of circulating miRNAs is a matter of debate. We and other groups have demonstrated that circulating miRNAs had the potential to be new biomarkers in patients with solid tumours for either early detection or evaluation of therapeutic efficiency ([@bib8], [@bib9]; [@bib4]).

In recent years, several studies have reported a series of circulating miRNAs differentially expressed in patients with GC, and most of these studies focussed on individual miRNAs selected from previous analyses on tissue samples and few with systematic miRNA profiling ([@bib10]; [@bib24]). However, the reported circulating miRNAs are not consistent among studies. [@bib17] performed serum miRNA profiling in 20 GC patients and 20 normal controls using Solexa sequencing and identified a five-miRNA signature (miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p) for GC diagnosis with the area under the receiver operating characteristic (ROC) curve (AUC) of \>0.800. Thereafter, another group analysed genome-wide serum miRNAs by miRNA microarray, and reported three miRNAs (miR-187\*, miR-371-5p and miR-378) significantly elevated in GC patients with the best AUC of 0.861 for miR-378 ([@bib16]). These two studies reported distinct serum miRNA profiles of GC. The inconsistency may be resulted from inclusion of different gastric tumour subtypes. For example, gastric non-cardia adenocarcinoma (GNCA) and cardia adenocarcinoma (GCA) have distinct clinical and epidemiologic features and each form might be characterised by a distinct expression profile of miRNA ([@bib7]; [@bib15]; [@bib25]). In addition, identifying differential circulating miRNAs by contrasting controls with GC patients of all tumour stages as a whole might lead to the risk of overrepresenting the aberrant miRNAs from the early-stage GC patients. Eventually, in spite of the promising discriminative ability of circulating miRNAs in studied samples, none of studies have evaluated the performance of these circulating miRNAs in independent samples. Therefore, large-scale, well-designed studies are needed to verify the clinical utility of circulating miRNAs for early detection of GC.

Gastric carcinogenesis is a multistep process that involves many environmental and genetic factors. It has been well demonstrated that the pathogenesis of GNCA initiates with chronic atrophic gastritis, and progresses through intestinal metaplasia and epithelial dysplasia ([@bib22]). A promising diagnostic biomarker may clearly discriminate the GNCA patients from those with precancerous lesions of GC. Herein, we stringently designed a four-phase study to identify a panel of circulating miRNAs as early diagnostic biomarkers of GNCA and evaluated their clinical usefulness in independent samples. In the discovery phase, we systematically screened the miRNA expression profile in plasma of 40 GNCA patients (stage I) and 40 matched controls by TaqMan low density array (TLDA) chips. Differentially expressed miRNAs were further validated in individual sample in the training phase using qRT--PCR assay. Subsequently, in an independent validation phase, the identified miRNAs were evaluated in additional samples, including 48 GNCA patients (stage I), 54 subjects with precancerous lesions of GC (PLGC) and 48 healthy subjects. Finally, the expression levels of the identified miRNAs were assessed in an external validation phase, including 18 stage I and 18 stage III/IV GNCA patients, and 18 stage I and 18 stage III/IV GCA patients.

Materials and methods
=====================

Study design and study population
---------------------------------

All of the subjects were recruited at the Yangzhou First People\'s Hospital, the Northern Jiangsu People\'s Hospital and the First Affiliated Hospital of Nanjing Medical University from January 2007 to November 2011 in Jiangsu province, China. All of the GC patients were confirmed by histopathology of surgical resected tumours and the tumour stage was determined according to the International Union Against Cancer\'s (UIAC) tumour-node-metastasis (TNM) system. In this study, we restricted the GNCA patients to those with tumour located at the body or antrum of stomach. Each subject was interviewed face-to-face to obtain demographic data and information on related risk factors using a structured questionnaire, including tobacco smoking and alcohol consuming. All of the participants were genetically unrelated, ethnic Han Chinese, and donated 5 ml of venous blood at the recruitment. Exclusion criteria included self-reported previous cancer history, surgical operation or chemo-radiotherapy before blood collection. This study was approved by the institutional review board of Nanjing Medical University, and the written informed consent was obtained from each participant.

Overall, a total of 320 participants were included in this study, and a four-phase study was designed ([Figure 1](#fig1){ref-type="fig"}). In the discovery phase, we performed miRNA profiling in two pooled samples from 40 GNCA patients at stage I and 40 healthy controls, respectively, using TLDA chips (V2.0; Applied Biosystems, Foster city, CA, USA). The controls were frequency matched to the GNCA patients on potential confounding factors including age, gender, smoking and drinking status. In the training phase, the differentially expressed miRNAs discovered via TLDA chips were confirmed by qRT--PCR in the same sample set of the discovery phase individually. These 80 subjects were used to estimate parameters of the identified miRNAs for GNCA diagnosis. In the validation phase, the diagnostic performance of the miRNAs identified by the training phase was independently evaluated in additional 150 subjects (48 GNCA patients at stage I, 54 PLGCs and 48 healthy subjects). The PLGCs included 18 chronic atrophic gastritis, 18 intestinal metaplasia and 18 epithelial dysplasia patients. Both the PLGCs and healthy subjects were also frequency matched to the GNCA patients on the factors of age, gender, smoking and drinking status. In the external validation phase, we enrolled 18 GNCA patients at stage I, 18 GNCA patients at stage III/IV, 18 GCA patients at stage I, 18 GCA patients at stage III/IV and 18 frequency-matched controls to assess the extensionality of the identified miRNAs. In addition, to determine the secretory potential of the identified miRNAs, GC cell lines were cultured and the expression of miRNAs in culture media was measured by qRT--PCR.

RNA isolation from plasma and culture medium
--------------------------------------------

The plasma was separated from venous blood within 24 h after sample collection by centrifugation at 4000 r.p.m. for 10 min. Two GC cell lines, BGC823 and MGC803, were cultured and a fraction of the culture media was collected at 0, 24 and 48 h after the initial seeding of cells in 10 cm dishes. In the absence of megascopic haemolysis for plasma samples, the plasma and culture media samples were further resolved by a 15-min high-speed centrifugation at 12 000 r.p.m. at 4 °C to completely remove cell debris. The supernatant samples were stored at −80 °C until analysis. A modified method was used to isolate the total RNAs ([@bib13]). Following the manufacturer\'s protocol, the Trizol Reagent (Invitrogen, Carlsbad, CA, USA) was used to denaturise plasma and the Qiagen miRNeasy Mini kit (Qiagen, Valencia, CA, USA) was used to collect and purify RNA. After denaturising, synthetic *C. elegans* miR-39 (cel-miR-39) (Takara, Japan) was spiked into each sample at a final concentration of 10^−4^ pmol *μ*l^−1^ for the purpose of controlling variability in RNA extraction and/or purification procedures.

TLDA chip and qRT--PCR assays
-----------------------------

Each plasma sample was pooled equally before RNA isolation with a total amount of 960 *μ*l that was used for the TLDA assay (V2.0; Applied Biosystems). After total RNA isolation, megaplex RT reactions and preamplification reactions were performed according to the manufacturer\'s protocol. Subsequently, 75 *μ*l 0.1 × TE was added to preamplification product, and 9 *μ*l diluted preamplification product was used to perform the RT--PCRs by dispensing 100 *μ*l of the PCR mix into each port of the TLDA chip. The RQ manager software (Applied Biosystems) was applied in the raw data analysis. *Δ*C~T~ and *ΔΔC*~T~ were calculated using the following formulae: *ΔC*~T~=*C*~T\ sample~−*C*~T\ cel-miR-39~ and *ΔΔC*~T~=*ΔC*~T\ case~−*ΔC*~T\ control~. Differentially expressed miRNAs were chosen as candidates for further confirmation by individual qRT--PCR according to the following two items: (i) having a *C*~T~ value of \<30 in at least one pool to ensure the enough abundance of miRNA for detection; (ii) \|*ΔΔC*~T~\|\>2, meaning four-fold altered expression between the GNCA patients and healthy controls to ensure favourable discriminative ability ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

For qRT--PCR, an equal volume (100 *μ*l for plasma and 200 *μ*l for cell-culture media) of sample was processed in RNA isolation for each subject. The total RNA was reverse transcribed to complementary DNA by using the TaqMan miRNA RT Kit and stem-loop RT primers (Applied Biosystems). The quantitative detection of miRNA was performed using the TaqMan PCR kit as implemented in the ABI 7900 Real-Time PCR System (Applied Biosystems). The reactions were initiated with a 384-well optical plate at 95 °C for 5 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Equal number of GNCA patients and controls was assigned in each plate and the expression levels of target miRNAs and control miRNA (cel-miR-39) were measured simultaneously. All reactions, including no template controls, were performed in triplicate. The relative expression levels of target miRNAs were calculated with 2^−*ΔΔ*CT^.

Statistical Analysis
--------------------

Demographic and clinical characteristics among groups were compared by *χ*^2^ test or one-way ANOVA. The differences of miRNAs among groups were tested using the Mann--Whitney unpaired test. Receiver operating characteristic curves were constructed in the training phase to obtain the optimal cutoff values for candidate miRNAs. We set the optimal cutoff value as the threshold, denoted as *t*, to code the expression level of the corresponding miRNA for each sample. The risk score for each miRNA, denoted as *s*, was calculated as follows:

Here, we used *i* to denote the *i*th sample, *j* the *j*th miRNA and *r* the expression level of miRNA. To additionally investigate the effectiveness of the five-miRNA panel for GNCA diagnosis, a mathematical formula was constructed, taking the contribution of each miRNA into account. Specifically, each subject was assigned a risk score function (RSF) according to a linear combination of the expression level of miRNA, weighted by the regression coefficient developed in the training phase. The RSF for subject *i* was:

Here, *s*~*ij*~ is the risk score for miRNA *j* on subject *i*, and *W*~*j*~ is the weighting for a given miRNA *j*. The regression coefficient of risk score for each miRNA was estimated by a univariate logistic regression model, and was used as the weighting to indicate the contribution of each miRNA to the RSF. The risk score coefficients developed in the training phase were also applied directly to the validation phase, in which the PLGC subjects and healthy subjects were combined as cancer-free controls to independently evaluate the clinical utility of identified miRNAs individually or in combination. Area under the ROC curve was used as an accuracy index for evaluating the diagnostic performance of the miRNAs. All the statistical analyses were performed with the Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC, USA). A *P*-value of \<0.05 was considered as statistically significant.

Results
=======

Characteristics of study subjects
---------------------------------

In the discovery and training phase, the healthy controls (*n*=40) were adequately frequency matched to the GNCA patients (*n*=40) with similar distributions of age, gender, smoking and drinking status (all *P*-values \>0.05) ([Table 1](#tbl1){ref-type="table"}). All GNCA patients were diagnosed with a stage I tumour at body or antrum of stomach. In the independent validation phase, two groups (*n*=48 and 102 for GNCAs and controls, respectively) were also well matched (all *P*-values \>0.05). The GNCA patients were also restricted to those with stage I tumour at the site of gastric body or antrum. In the external validation phase, five groups (18 subjects each) with different anatomic locations and clinical stages also showed similar distributions on age, gender, smoking and drinking status (all *P*-values \>0.05) ([Table 1](#tbl1){ref-type="table"}).

MiRNAs screening and individual qRT--PCR confirmation
-----------------------------------------------------

With an effort to identify stably, differentially expressed miRNAs in plasma, we screened a total of 667 human miRNAs by TLDA chips in pooled samples between the GNCA patients and healthy controls (40 subjects for each pool). We further selected candidate miRNAs that had a *C*~T~ value of \<30 in at least one pool and showed more than four-fold altered expression between the two pooled samples. As a result, five upregulated plasma miRNAs, including miR-16, miR-25, miR-92a, miR-451 and miR-486-5p, were subjected to individual qRT--PCR confirmation in the training phase ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Consistent with the results of the discovery phase, all of the five miRNAs had a significantly higher expression level in the GNCA patients as compared with controls ([Table 2](#tbl2){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}).

Independent validation of the five identified miRNAs in plasma
--------------------------------------------------------------

Next, we examined the expression levels of the five identified miRNAs in a larger independent sample set comprising of 48 GNCA patients and 102 cancer-free controls in the independent validation phase. As shown in [Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}, the differential expression patterns of the five miRNAs between the GNCA patients and controls were generally concordant between the validation and training phase, suggesting that these five miRNAs (miR-16, miR-25, miR-92a, miR-451and miR-486-5p) in plasma might serve as potential diagnostic markers in the early-stage GNCA.

Performance of the five-miRNA panel for early detection of the GNCA patients
----------------------------------------------------------------------------

To evaluate the performance of the miRNAs in discriminating the GNCA patients from cancer-free subjects, the discriminatory parameters were first developed in the training phase and were further independently assessed in the validation phase. The optimal cutoff value for individual miRNA was determined according to the ROC curve for each miRNA in the training phase ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). As expected, the performance of the individual miRNA was attractive in the training phase with AUCs being 0.925, 0.925, 0.913, 0.850 and 0.863 for miR-16, miR-25, miR-92a, miR-451 and miR-486-5p, respectively ([Table 3](#tbl3){ref-type="table"}). Interestingly, based on the cutoff values developed in the training phase, the AUCs, though reducing, were still very favourable in the validation phase with values varying from 0.694 to 0.790, which may reflect the practical utility of individual miRNA in the diagnosis of the GNCA patients.

To assess the diagnostic utility of this five-miRNA panel, a linear combination of the risk score of the five miRNAs weighted by the regression coefficient was used to calculate an RSF of the five-miRNA panel for each subject. The RSF was calculated as follows: RSF=(5.142 × risk score of miR-16)+(5.609 × risk score of miR-25)+(5.398 × risk score of miR-92a)+(4.043 × risk score of miR-451)+(4.181 × risk score of miR-486-5p), where the regression coefficients were derived from subjects in the training phase. Similar to but better than the individual miRNA, in the training phase, the AUC of the five-miRNA panel was 0.989 and the diagnostic sensitivity and specificity were 97.5% and 87.5%, respectively ([Figure 3](#fig3){ref-type="fig"}). Importantly, in the validation phase, the miRNA panel also showed relatively high ability in discriminating the GNCA patients from the cancer-free controls with an AUC of 0.812 (sensitivity=72.9% and specificity=89.2%) ([Figure 3](#fig3){ref-type="fig"}). These results indicate that, although one particular miRNA in plasma may help distinguish different subgroups, a combination of a panel of miRNAs may have a great potential to offer much more sensitive and specific diagnostic test.

External validation in advanced GNCA and GCA patients
-----------------------------------------------------

To further assess the extensionality of the identified miRNAs in GC patients at different anatomic sites and clinical stages, we analysed the expression levels of the five identified miRNAs in 18 GNCA patients diagnosed at stage I, 18 GNCA patients at stage III or IV, 18 GCA patients at stage I, 18 GCA patients at stage III or IV and 18 matched controls ([Table 1](#tbl1){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}). As compared with the controls, all of the five miRNAs were consistently overexpressed in all GC groups (all *P*-values \<0.05) ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}), suggesting that these five miRNAs may be useful in detection of all GC patients.

Expression of the five identified miRNAs in GC cell-culture medium
------------------------------------------------------------------

In addition, we determined whether the identified miRNAs (miR-16, miR-25, miR-92a, miR-451 and miR-486-5p) act as secretory miRNAs and are excreted into the culture media by BGC823 and MGC803 cell lines. We found that miR-16, miR-25 and miR-92a levels in media of BGC823 and MGC803 increased with increasing cell counts (0.5--2 × 10^6^ cells per well) and incubation time (24 and 48 h), whereas miR-451 and miR-486-5p levels did not change in either cell line ([Figure 4](#fig4){ref-type="fig"}). These data suggest that miR-16, miR-25 and miR-92a but not miR-451 or miR-486-5p may be secretory miRNAs.

Discussion
==========

In this study, we systematically screened the miRNA profile in plasma from the GNCA patients and healthy controls, and identified five differentially expressed miRNAs (miR-16, miR-25, miR-92a, miR-451 and miR-486-5p), which were confirmed in independent samples. More importantly, the five-miRNA panel showed high diagnostic performance in discriminating the early-stage GNCA patients from the cancer-free subjects. Our findings highlight that circulating miRNAs may be a class of novel, non-invasive diagnostic biomarkers with sufficient diagnostic accuracy, and a specified miRNA panel can be of great value in mass screening or early detection of GC.

Among the five miRNAs identified in this study, miR-451 and miR-486-5p have been reported to be potentially useful biomarkers for GC ([@bib12]). In their study, candidate miRNAs were screened by comparing pre- and post-operative paired plasma of GC, and the expression levels of nine miRNAs were markedly decreased in the post-operative plasma. Among these miRNAs, miR-451 and miR-486-5p abundant in plasma were selected and validated in more pre- and post-operative plasma ([@bib12]). These two miRNAs also showed high AUCs (0.96 and 0.92, respectively) as comparing GC patients (*n*=56) with healthy controls (*n*=30) ([@bib12]). These findings were consistent with our results. Interestingly, the other three miRNAs (miR-16, miR-25 and miR-92a) identified in the current study were also among the nine candidate miRNAs, though not being subject to further study, reported to be markedly decreased in post-operative plasma by [@bib12]. In view of different study designs, populations and platforms between two groups, the consistent findings make us confident that the identified plasma miRNAs in this study may be in great potentials for GC mass screening or early detection, though further perspective clinical trials are warranted to define the usefulness of the five-miRNA panel in clinical application.

Emerging evidence suggests that circulating miRNAs are cancer related, but the releasing mechanism is still an open topic ([@bib28]; [@bib30]; [@bib1]). Some researchers believe they are produced from tumour tissues, which leak or actively transport them into the bloodstream ([@bib30]). This hypothesis appears to be reasonable as interpreting our results in part. The levels of miR-16, miR-25 and miR-92a upregulated in GC plasma were also reported to be increased in GC tissue samples ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). In the current study, our results suggested that these three miRNAs were excreted into the culture media by BGC823 and MGC803 cell lines and might act as secretory miRNAs. However, there is contradiction of miR-451 and miR-486-5p expression in plasma and GC tissues ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). The downregulation of miR-451 was significantly associated with gastric adenocarcinomas as compared with normal gastric mucosa ([@bib2]; [@bib27]; [@bib12]). Similarly, [@bib19] identified miR-486 as a significantly downregulated miRNA in primary GC tumours and GC cell lines, and similar trend was also reported by [@bib12] and [@bib26]. Of interest, in the current study, the expression levels of miR-451 and miR-486-5p did not change in culture medium of GC cell lines as cell counts and incubation time increased. The selective release of specific cellular miRNAs from the tumour cells themselves or from normal cells might explain these apparently paradoxical findings ([@bib21]). Nevertheless, further experimental studies are required to elucidate the releasing mechanism in specific to these five miRNAs, although this may have no substantial influence on the clinical application for GNCA diagnosis as biomarkers.

Moreover, understanding the miRNA targets and the molecular mechanisms by which the miRNAs regulate GC development may promote their clinical application. [@bib31] reported that miR-16 had a role in the regulation of Wip1 phosphatase in the DNA damage response. [@bib11] showed that miR-25 targets p57 and ectopic expression of miR-25 in GC may result in activation of Cdk2 and facilitation of G1/S phase transition. MiR-92a, a member of miR-17-92 cluster, seems to be tightly linked to the functions of the E2F family of transcription factors, which are critical regulators of the cell cycle and the apoptosis ([@bib20]). Microarray and bioinformatic analysis identified that the oncogene macrophage migration inhibitory factor (MIF) may be the potential target of miR-451, indicating that miR-451 may act as a regulator of cancer proliferation ([@bib2]). As for miR-486-5p, it may direct targeting and inhibition of OLFM4 expression, and function as a tumour-suppressor miRNA in GC ([@bib19]). Nevertheless, additional investigation of the regulatory mechanism of these miRNAs may improve our understanding of the molecular pathogenesis of GC as well as the effectiveness in identifying potential therapy targets and surveillance markers for GC.

This study may have several strengths. First, in the initial screening phase, we restricted GC patients to those with GNCA at stage I, which may exclude the potential confounding due to distinct profiles between subtypes and tumour stages. Our study clearly demonstrated that the five identified miRNAs were consistently elevated in the early-stage GNCA patients. We further explored the extensionality of these miRNAs in GCA and advanced GNCA patients and the results indicated that these five miRNAs may be applicable for the early diagnose of all GC patients, though further large-scale, well-designed studies are warranted to validate these findings. Second, the five-miRNA panel was systematically screened through miRNA profiling on the GNCA patients and healthy controls using TLDA chips, which was validated in both additional platform and independent samples. These may increase the reliability of the findings. Third, in the current study, we selected candidate miRNAs that were abundantly expressed in plasma to ensure the feasibility of examination in clinical practice. Importantly, the clinical utility of identified miRNAs was assessed in independent samples including the early-stage GNCA patients, PLGC subjects and healthy controls. These efforts may offer us an miRNA panel with great potential in early diagnosis of GC.

In summary, we conducted a comprehensive assessment of the diagnostic usefulness of an miRNA panel in plasma for GNCA in a tailored investigation with independent validation. The sensitivity and the specificity were high and the discriminative accuracy was satisfactory for the diagnosis of the early-stage GC. Our work will serve as a basis for further large-scale validation before circulating miRNAs enable their introduction into the clinic setting.
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![**Overview of the study design.** Abbreviations: GCA= gastric cardia adenocarcinoma; GNCA= gastric non-cardia adenocarcinoma; TLDA= TaqMan low density array; qRT--PCR= quantitative reverse-transcriptase PCR assay; ROC= receiver operating characteristic curve.](bjc2014119f1){#fig1}

![**Expression levels of the five miRNAs in plasma in the training and validation phases.** The y axis represents relative expression of miRNAs normalised to cel-miR-39. GNCA, gastric non-cardia adenocarcinoma.](bjc2014119f2){#fig2}

![**The discriminative ability of the five-miRNA panel between the GNCA patients and cancer-free subjects by receiver operating characteristic curve (ROC) analysis.** Red line, the training phase (AUC=0.989, sensitivity=97.5%, specificity=87.5%); green line, the validation phase (AUC=0.812, sensitivity=72.9%, specificity=89.2%); blue line, two phases combined (AUC=0.890, sensitivity=84.1%, specificity=90.8%).](bjc2014119f3){#fig3}

![**Expression of the five identified miRNAs in culture media of gastric cancer (GC) cell lines (BGC823 and MGC803).** MiR-16, miR-25 and miR-92a levels in media of both BGC823 and MGC803 increased with increased cell counts (0.5--2 × 10^6^ cells per well) and longer incubation intervals (24 and 48 h), whereas miR-451 and miR-486-5p levels did not change in either cell line. The y axis represents relative expression of miRNAs normalised to cel-miR-39 and cell-culture media at 0 h.](bjc2014119f4){#fig4}

###### Characteristics of the subjects included in this study

                         **Discovery/Training phase (*****n***=**80)**   **Independent validation phase (*****n***=**150)**   **External validation phase (*****n***=**90)**                                           
  --------------------- ----------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ------------- ------------- ------------ ------------
  Number                                    *n*=40                                             *n*=40                                            *n*=102                         *n*=48        *n*=18        *n*=36       *n*=36
  Age (mean±s.d.)                         53.55±10.11                                       53.83±10.34                                        54.03±10.45                     56.63±10.37   55.11±11.89   55.78±8.77   55.36±6.94
  **Gender**                                                                                                                                                                                                           
  Male                                     29 (72.5)                                         29 (72.5)                                          72 (70.6)                       35 (72.9)     13 (72.2)    27 (75.0)    26 (72.2)
  Female                                   11 (27.5)                                         11 (27.5)                                          30 (29.4)                       13 (27.1)     5 (27.8)      9 (25.0)    10 (27.8)
  **Smoking status**                                                                                                                                                                                                   
  Never                                    23 (57.5)                                         23 (57.5)                                          53 (52.0)                       24 (50.0)     12 (66.7)    26 (72.2)    22 (61.1)
  Ever                                     17 (42.5)                                         17 (42.5)                                          49 (48.0)                       24 (50.0)     6 (33.3)     10 (27.8)    14 (38.9)
  **Drinking status**                                                                                                                                                                                                  
  Never                                    26 (65.0)                                         24 (60.0)                                          70 (68.6)                       30 (62.5)     15 (83.3)    26 (72.2)    24 (66.7)
  Ever                                     14 (35.0)                                         16 (40.0)                                          32 (31.4)                       18 (37.5)     3 (16.7)     10 (27.8)    12 (33.3)
  **Tumour site**                                                                                                                                                                                                      
  Cardia                                                                                         0                                                                                  0                          0        36 (100.0)
  Body                                                                                       20 (50.0)                                                                          25 (52.1)                  17 (47.2)        0
  Antrum                                                                                     20 (50.0)                                                                          23 (47.9)                  19 (52.8)        0
  **Tumour stage**                                                                                                                                                                                                     
  Ia                                                                                         20 (50.0)                                                                          32 (66.7)                  11 (30.6)     6 (16.7)
  Ib                                                                                         20 (50.0)                                                                          16 (33.3)                   7 (19.4)    12 (33.3)
  III                                                                                            0                                                                                  0                       9 (25.0)    12 (33.3)
  IV                                                                                             0                                                                                  0                       9 (25.0)     6 (16.7)

Abbreviations: GCA=gastric cardia adenocarcinoma; GNCA=gastric non-cardia adenocarcinoma.

###### Results of five differentially expressed miRNAs between the GNCA patients and controls identified by TLDA chips in the discovery phase and confirmed by individual qRT--PCR assay in the training phase

               **Controls (*****n***=**40)**   **GNCA patients (*****n***=**40)**                                                
  ------------ ------------------------------- ------------------------------------ ------ ------- ------------- ------- ------- ----------------
  miR-16       0.19                            9.96±11.72                           6.51   −2.49   93.37±89.26   61.39   −2.68    8.71 × 10^−13^
  miR-25       6.43                            0.61±0.39                            0.58   3.51    4.17±4.19     2.69    −2.92    8.71 × 10^−13^
  miR-92a      0.13                            7.10±5.97                            5.15   −2.20   38.69±30.51   26.63   −2.33    3.72 × 10^−12^
  miR-451      4.51                            3.10±2.79                            2.04   1.76    22.76±29.78   13.57   −2.75    6.42 × 10^−11^
  miR-486-5p   3.72                            7.28±6.51                            5.32   0.37    66.19±82.92   35.63   −3.35    1.26 × 10^−9^

Abbreviations: GNCA=gastric non-cardia adenocarcinoma; microRNA=miRNA; TLDA=TaqMan low density array; qRT--PCR=quantitative reverse-transcriptase PCR.

*ΔC*~T~=*C*~T\ sample~−*C*~T\ cel-miR-39~.

*ΔΔC*~T~=*ΔC*~T\ GNCA~−*ΔC*~T\ control~.

Mann--Whitney unpaired test for rank sum.

###### Discriminative ability of individual miRNAs between the GNCA patients and controls

  **Stage**           **miRNA**[a](#t3-fn2){ref-type="fn"}  **Cutoff value**[b](#t3-fn3){ref-type="fn"}   **Sensitivity**   **Specificity**   **AUC**
  ------------------ -------------------------------------- --------------------------------------------- ----------------- ----------------- ---------
  Training phase                     miR-16                 0.255                                         0.900             0.950             0.925
                                     miR-25                 0.014                                         0.875             0.975             0.925
                                    miR-92a                 0.095                                         0.975             0.850             0.913
                                    miR-451                 0.040                                         0.950             0.750             0.850
                                   miR-486-5p               0.178                                         0.775             0.950             0.863
  Validation phase                   miR-16                 0.255                                         0.625             0.912             0.768
                                     miR-25                 0.014                                         0.417             0.971             0.694
                                    miR-92a                 0.095                                         0.729             0.735             0.732
                                    miR-451                 0.040                                         0.688             0.892             0.790
                                   miR-486-5p               0.178                                         0.646             0.912             0.779
  Combined phase                     miR-16                 0.255                                         0.750             0.923             0.836
                                     miR-25                 0.014                                         0.625             0.972             0.798
                                    miR-92a                 0.095                                         0.841             0.768             0.804
                                    miR-451                 0.040                                         0.807             0.852             0.829
                                   miR-486-5p               0.178                                         0.705             0.923             0.814

Abbreviations: AUC=area under the ROC curve; GNCA=gastric non-cardia adenocarcinoma; microRNA=miRNA; ROC=receiver operating characteristic.

The miRNA expression level was coded as 0 or 1 for each subject according to the optimal cutoff value.

The optimal cutoffs were defined by the ROC curves developed in the training phase.

[^1]: These authors contributed equally to this work.
